294 related articles for article (PubMed ID: 24331068)
1. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
[No Abstract] [Full Text] [Related]
2. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
[TBL] [Abstract][Full Text] [Related]
3. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
Nguyen M; Ball R; Midthun K; Lieu TA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
Ball R
Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
[TBL] [Abstract][Full Text] [Related]
5. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
[No Abstract] [Full Text] [Related]
6. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
7. Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program.
Lieu TA; Nguyen MD; Ball R; Martin DB
Vaccine; 2012 Apr; 30(18):2824-30. PubMed ID: 22394993
[TBL] [Abstract][Full Text] [Related]
8. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.
Forrow S; Campion DM; Herrinton LJ; Nair VP; Robb MA; Wilson M; Platt R
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():12-7. PubMed ID: 22262588
[TBL] [Abstract][Full Text] [Related]
9. Drug-safety pilot makes the grade.
Ledford H
Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
[No Abstract] [Full Text] [Related]
10. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.
Toh S; Baker MA; Brown JS; Kornegay C; Platt R;
JAMA Intern Med; 2013 May; 173(9):817-9. PubMed ID: 23529063
[No Abstract] [Full Text] [Related]
11. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
12. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1988 Apr; 37(13):197-200. PubMed ID: 2832717
[No Abstract] [Full Text] [Related]
13. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.
Baker MA; Lieu TA; Li L; Hua W; Qiang Y; Kawai AT; Fireman BH; Martin DB; Nguyen MD
Am J Epidemiol; 2015 Apr; 181(8):608-18. PubMed ID: 25769306
[TBL] [Abstract][Full Text] [Related]
14. Adverse events following immunization: is this time for the use of WHO causality assessment?
Tafuri S; Gallone MS; Calabrese G; Germinario C
Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance for adverse events following immunization.
Crawford NW; Clothier H; Hodgson K; Selvaraj G; Easton ML; Buttery JP
Expert Rev Vaccines; 2014 Feb; 13(2):265-76. PubMed ID: 24350637
[TBL] [Abstract][Full Text] [Related]
16. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
Qato DM; Alexander GC
JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
[No Abstract] [Full Text] [Related]
17. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
18. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
Kuehn BM
JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
[No Abstract] [Full Text] [Related]
19. Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.
Top KA; Constantinescu CM; Laflèche J; Bettinger JA; Scheifele DW; Vaudry W; Halperin SA; Law BJ
Vaccine; 2013 Nov; 31(48):5700-5. PubMed ID: 24099871
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the completeness and accuracy of MedWatch data.
Getz KA; Stergiopoulos S; Kaitin KI
Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
